| Year |
Citation |
Score |
| 2023 |
Sánchez-Soto M, Boldizsar NM, Schardien KA, Madaras NS, Willette BKA, Inbody LR, Dasaro C, Moritz AE, Drube J, Haider RS, Free RB, Hoffman C, Sibley DR. G Protein-Coupled Receptor Kinase 2 Selectively Enhances β-Arrestin Recruitment to the D Dopamine Receptor through Mechanisms That Are Independent of Receptor Phosphorylation. Biomolecules. 13. PMID 37892234 DOI: 10.3390/biom13101552 |
0.816 |
|
| 2023 |
Boateng CA, Nilson AN, Placide R, Pham ML, Jakobs FM, Boldizsar N, McIntosh S, Stallings LS, Korankyi IV, Kelshikar S, Shah N, Panasis D, Muccilli A, Ladik M, Maslonka B, ... ... Sibley DR, et al. Pharmacology and Therapeutic Potential of Benzothiazole Analogues for Cocaine Use Disorder. Journal of Medicinal Chemistry. PMID 37646374 DOI: 10.1021/acs.jmedchem.3c00734 |
0.676 |
|
| 2023 |
Sibley DR, Nilson AN, Moritz AE, Shi L. Dopamine receptor divergence revealed using a common ligand. Trends in Pharmacological Sciences. PMID 37599183 DOI: 10.1016/j.tips.2023.08.002 |
0.823 |
|
| 2023 |
Enriquez-Traba J, Yarur-Castillo HE, Flores RJ, Weil T, Roy S, Usdin TB, LaGamma CT, Arenivar M, Wang H, Tsai VS, Moritz AE, Sibley DR, Moratalla R, Freyberg ZZ, Tejeda HA. Dissociable control of motivation and reinforcement by distinct ventral striatal dopamine receptors. Biorxiv : the Preprint Server For Biology. PMID 37425766 DOI: 10.1101/2023.06.27.546539 |
0.815 |
|
| 2023 |
Moritz AE, Madaras NS, Rankin ML, Inbody LR, Sibley DR. Delineation of G Protein-Coupled Receptor Kinase Phosphorylation Sites within the D Dopamine Receptor and Their Roles in Modulating β-Arrestin Binding and Activation. International Journal of Molecular Sciences. 24. PMID 37047571 DOI: 10.3390/ijms24076599 |
0.835 |
|
| 2022 |
Free RB, Nilson AN, Boldizsar NM, Doyle TB, Rodriguiz RM, Pogorelov VM, Machino M, Lee KH, Bertz JW, Xu J, Lim HD, Dulcey AE, Mach RH, Woods JH, Lane JR, ... ... Sibley DR, et al. Identification and Characterization of ML321: A Novel and Highly Selective D Dopamine Receptor Antagonist with Efficacy in Animal Models That Predict Atypical Antipsychotic Activity. Acs Pharmacology & Translational Science. 6: 151-170. PMID 36654757 DOI: 10.1021/acsptsci.2c00202 |
0.686 |
|
| 2022 |
Aslanoglou D, Bertera S, Friggeri L, Sánchez-Soto M, Lee J, Xue X, Logan RW, Lane JR, Yechoor VK, McCormick PJ, Meiler J, Free RB, Sibley DR, Bottino R, Freyberg Z. Dual pancreatic adrenergic and dopaminergic signaling as a therapeutic target of bromocriptine. Iscience. 25: 104771. PMID 35982797 DOI: 10.1016/j.isci.2022.104771 |
0.665 |
|
| 2021 |
Free RB, Cuoco CA, Xie B, Namkung Y, Prabhu VV, Willette BKA, Day MM, Sanchez-Soto M, Lane JR, Laporte SA, Shi L, Allen JE, Sibley DR. Pharmacological characterization of the imipridone anti-cancer drug ONC201 reveals a negative allosteric mechanism of action at the D dopamine receptor. Molecular Pharmacology. PMID 34353882 DOI: 10.1124/molpharm.121.000336 |
0.866 |
|
| 2021 |
Sibley DR, Luderman KD, Free RB, Shi L. Novel Cryo-EM structures of the D1 dopamine receptor unlock its therapeutic potential. Signal Transduction and Targeted Therapy. 6: 205. PMID 34023856 DOI: 10.1038/s41392-021-00630-3 |
0.868 |
|
| 2021 |
Aslanoglou D, Bertera S, Sánchez-Soto M, Benjamin Free R, Lee J, Zong W, Xue X, Shrestha S, Brissova M, Logan RW, Wollheim CB, Trucco M, Yechoor VK, Sibley DR, Bottino R, et al. Dopamine regulates pancreatic glucagon and insulin secretion via adrenergic and dopaminergic receptors. Translational Psychiatry. 11: 59. PMID 33589583 DOI: 10.1038/s41398-020-01171-z |
0.364 |
|
| 2020 |
Luderman KD, Jain P, Benjamin Free R, Conroy JL, Aubé J, Sibley DR, Frankowski KJ. Development of Pyrimidone D1 Dopamine Receptor Positive Allosteric Modulators. Bioorganic & Medicinal Chemistry Letters. 127696. PMID 33221389 DOI: 10.1016/j.bmcl.2020.127696 |
0.863 |
|
| 2020 |
Moritz AE, Bonifazi A, Guerrero AM, Kumar V, Free RB, Lane JR, Verma RK, Shi L, Newman AH, Sibley DR. Evidence for a stereoselective mechanism for bitopic activity by extended-length antagonists of the D3 dopamine receptor. Acs Chemical Neuroscience. PMID 32969645 DOI: 10.1021/acschemneuro.0c00425 |
0.86 |
|
| 2020 |
Ågren R, Zeberg H, Maciej Stępniewski T, Free RB, Reilly SW, Luedtke RR, Århem P, Ciruela F, Sibley DR, Mach RH, Selent J, Nilsson J, Sahlholm K. A ligand with two modes of interaction with the dopamine D2 receptor - An induced-fit mechanism of insurmountable antagonism. Acs Chemical Neuroscience. PMID 32865974 DOI: 10.1021/Acschemneuro.0C00477 |
0.744 |
|
| 2020 |
Moritz AE, Free RB, Weiner WS, Akano EO, Gandhi D, Abramyan A, Keck TM, Ferrer M, Hu X, Southall N, Steiner J, Aubé J, Shi L, Frankowski KJ, Sibley DR. Discovery, Optimization and Characterization of ML417: A Novel and Highly Selective D3 Dopamine Receptor Agonist. Journal of Medicinal Chemistry. PMID 32342685 DOI: 10.1021/Acs.Jmedchem.0C00424 |
0.849 |
|
| 2020 |
Castello J, Cortés M, Malave L, Kottmann A, Sibley DR, Friedman E, Rebholz H. Publisher Correction: The Dopamine D5 receptor contributes to activation of cholinergic interneurons during L-DOPA induced dyskinesia. Scientific Reports. 10: 4974. PMID 32165689 DOI: 10.1038/S41598-020-61832-3 |
0.525 |
|
| 2020 |
Castello J, Cortés M, Malave L, Kottmann A, Sibley DR, Friedman E, Rebholz H. The Dopamine D5 receptor contributes to activation of cholinergic interneurons during L-DOPA induced dyskinesia. Scientific Reports. 10: 2542. PMID 32054879 DOI: 10.1038/S41598-020-59011-5 |
0.559 |
|
| 2020 |
Sanchez-Soto M, Verma RK, Willette BKA, Gonye EC, Moore AM, Moritz AE, Boateng CA, Yano H, Free RB, Shi L, Sibley DR. A structural basis for how ligand binding site changes can allosterically regulate GPCR signaling and engender functional selectivity. Science Signaling. 13. PMID 32019899 DOI: 10.1126/Scisignal.Aaw5885 |
0.841 |
|
| 2020 |
Prabhu VV, Morrow S, Cuoco CA, Kawakibi AR, Jung J, Madhukar N, Garnett MJ, McDermott U, Benes CH, Wechsler-Reya R, Anantharaman L, Charter N, Rucker JB, Doranz BJ, Basken J, ... ... Sibley DR, et al. Abstract 5688: IND-enabling characterization of ONC206 as the next bitopic antagonist for oncology Cancer Research. 80: 5688-5688. DOI: 10.1158/1538-7445.Am2020-5688 |
0.805 |
|
| 2020 |
Schardien KA, Soto MS, Inbody L, Berchiche Y, Kehrl JH, Bradfield C, Free RB, Sibley DR. Investigation of G protein‐coupled receptor kinase 2 (GRK2) regulation of D
2
dopamine receptor signaling: effects of GRK2 functional domains and pharmacologic and genetic inhibition of GRK2 activity The Faseb Journal. 34: 1-1. DOI: 10.1096/Fasebj.2020.34.S1.05825 |
0.851 |
|
| 2020 |
Rocereta J, Free RB, Garcia AD, Southall N, Shi L, Lane R, Wetsel W, Marugan JJ, Sibley DR. Optimization of a novel D
2
dopamine receptor antagonist with unprecedented selectivity as a therapeutic to treat psychosis and other neuropsychiatric disorders The Faseb Journal. 34: 1-1. DOI: 10.1096/Fasebj.2020.34.S1.04066 |
0.766 |
|
| 2020 |
Sanchez-Soto M, Schardien KA, Inbody L, Free RB, Sibley DR. G protein‐coupled receptor kinase 2 can enhance beta‐arrestin recruitment to the D
2
dopamine receptor in the absence of receptor phosphorylation The Faseb Journal. 34: 1-1. DOI: 10.1096/Fasebj.2020.34.S1.03478 |
0.865 |
|
| 2020 |
Akano EO, Casazza JA, Dranchak P, Moritz AE, Free RB, Inglese J, Sibley DR. Development of a dopaminergic neurodegeneration assay using laser cytometry of
Caenorhabditis elegans
models of Parkinson’s disease The Faseb Journal. 34: 1-1. DOI: 10.1096/Fasebj.2020.34.S1.02481 |
0.753 |
|
| 2020 |
Moritz AE, Inbody LR, Gandhi DM, Akano E, Fearce C, Free RB, Barnaeva ES, Hu X, Southall NT, Ferrer M, Keck TM, Frankowski KJ, Sibley DR. Structure‐Activity Relationships of a Negative Allosteric Modulator of the D3 Dopamine Receptor and Investigation of its Binding Site The Faseb Journal. 34: 1-1. DOI: 10.1096/Fasebj.2020.34.S1.02441 |
0.855 |
|
| 2019 |
Bocarsly ME, da Silva E Silva D, Kolb V, Luderman KD, Shashikiran S, Rubinstein M, Sibley DR, Dobbs LK, Alvarez VA. A Mechanism Linking Two Known Vulnerability Factors for Alcohol Abuse: Heightened Alcohol Stimulation and Low Striatal Dopamine D2 Receptors. Cell Reports. 29: 1147-1163.e5. PMID 31665630 DOI: 10.1016/J.Celrep.2019.09.059 |
0.799 |
|
| 2019 |
Bonaventura J, Eldridge MAG, Hu F, Gomez JL, Sanchez-Soto M, Abramyan AM, Lam S, Boehm MA, Ruiz C, Farrell MR, Moreno A, Galal Faress IM, Andersen N, Lin JY, Moaddel R, ... ... Sibley DR, et al. High-potency ligands for DREADD imaging and activation in rodents and monkeys. Nature Communications. 10: 4627. PMID 31604917 DOI: 10.1038/S41467-019-12236-Z |
0.313 |
|
| 2019 |
Keck TM, Free RB, Day MM, Brown SL, Maddaluna MS, Fountain G, Cooper C, Fallon B, Holmes M, Stang C, Burkhardt R, Bonifazi A, Ellenberger MP, Newman AH, Sibley DR, et al. Dopamine D4 Receptor-Selective Compounds Reveal Structure-Activity Relationships that Engender Agonist Efficacy. Journal of Medicinal Chemistry. PMID 30883109 DOI: 10.1021/Acs.Jmedchem.9B00231 |
0.864 |
|
| 2019 |
Farino ZJ, Morgenstern TJ, Maffei A, Quick M, De Solis AJ, Wiriyasermkul P, Freyberg RJ, Aslanoglou D, Sorisio D, Inbar BP, Free RB, Donthamsetti P, Mosharov EV, Kellendonk C, Schwartz GJ, ... Sibley DR, et al. New roles for dopamine D and D receptors in pancreatic beta cell insulin secretion. Molecular Psychiatry. PMID 30626912 DOI: 10.1038/S41380-018-0344-6 |
0.742 |
|
| 2019 |
Beaulieu J, Borrelli E, Carlsson A, Caron MG, Civelli O, Espinoza S, Fisone G, Gainetdinov RR, Grandy DK, Kebabian JW, Langer SZ, Missale MC, Neve KA, Scatton B, Schwartz J, ... ... Sibley DR, et al. Dopamine receptors (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database Iuphar/Bps Guide to Pharmacology Cite. 2019. DOI: 10.2218/gtopdb/f20/2019.4 |
0.646 |
|
| 2019 |
Prabhu VV, Kawakibi AR, Madhukar N, Garnett MJ, McDermott U, Benes CH, Anantharaman L, Charter N, Deacon S, VanEngelenburg A, Rucker JB, Doranz BJ, Rusert J, Wechsler-Reya R, Elemento O, ... ... Sibley DR, et al. Abstract 3877: IND-enabling characterization of DRD2/3 imipridone antagonist ONC206 for oncology Cancer Research. 79: 3877-3877. DOI: 10.1158/1538-7445.Sabcs18-3877 |
0.685 |
|
| 2019 |
Benjamin Free R, Cuoco C, Prabhu V, Willette B, Day M, Anantharaman L, Sulli C, Davidson E, Deacon S, Rucker J, Charter N, Doranz B, Oster W, Stogniew M, Robert Lane J, ... Sibley D, et al. EXTH-33. RECEPTOR PHARMACOLOGY OF ONC201: THE FIRST BITOPIC DRD2 ANTAGONIST FOR CLINICAL NEURO-ONCOLOGY Neuro-Oncology. 21: vi89-vi89. DOI: 10.1093/Neuonc/Noz175.365 |
0.85 |
|
| 2019 |
Prabhu V, Cuoco C, Jung J, Rahman Kawakibi A, Willette B, Day M, Anantharaman L, Charter N, Rucker J, Doranz B, Oster W, Stogniew M, Gilbert M, Benjamin Free R, Sibley D, et al. DDIS-20. IMIPRIDONE STRUCTURE ACTIVITY RELATIONSHIP UNCOVERS ONC206 AS THE NEXT BITOPIC DRD2 ANTAGONIST FOR ONCOLOGY WITH DIFFERENTIATED RECEPTOR PHARMACOLOGY Neuro-Oncology. 21: vi67-vi67. DOI: 10.1093/Neuonc/Noz175.271 |
0.841 |
|
| 2019 |
Freyberg Z, Farino Z, Morgenstern T, Maffei A, Quick M, De Solis A, Wiriyasermkul P, Freyberg R, Aslanoglou D, Sorisio D, Inbar B, Free RB, Donthamsetti P, Mosharov E, Kellendonk C, ... ... Sibley D, et al. 50. New Roles for Peripheral Dopamine D2-Like Receptors in Antipsychotic Drug-Induced Metabolic Dysfunction Biological Psychiatry. 85: S21. DOI: 10.1016/J.Biopsych.2019.03.064 |
0.749 |
|
| 2018 |
Sibley DR, Shi L. A new era of rationally designed antipsychotics. Nature. 555: 170-172. PMID 32095019 DOI: 10.1038/d41586-018-02328-z |
0.465 |
|
| 2018 |
Luderman KD, Conroy JL, Free RB, Southall N, Ferrer M, Sanchez-Soto M, Moritz AE, Willette BKA, Fyfe TJ, Jain P, Titus S, Hazelwood LA, Aube J, Lane JR, Frankowski KJ, ... Sibley DR, et al. Identification of positive allosteric modulators of the D1 dopamine receptor that act at diverse binding sites. Molecular Pharmacology. PMID 30068735 DOI: 10.1124/Mol.118.113175 |
0.861 |
|
| 2018 |
Chun LS, Vekariya RH, Free RB, Li Y, Lin DT, Su P, Liu F, Namkung Y, Laporte SA, Moritz AE, Aubé J, Frankowski KJ, Sibley DR. Structure-Activity Investigation of a G Protein-Biased Agonist Reveals Molecular Determinants for Biased Signaling of the DDopamine Receptor. Frontiers in Synaptic Neuroscience. 10: 2. PMID 29515433 DOI: 10.3389/Fnsyn.2018.00002 |
0.828 |
|
| 2018 |
Verma RK, Abramyan AM, Michino M, Free RB, Sibley DR, Javitch JA, Lane JR, Shi L. The E2.65A mutation disrupts dynamic binding poses of SB269652 at the dopamine D2 and D3 receptors. Plos Computational Biology. 14: e1005948. PMID 29337986 DOI: 10.1371/Journal.Pcbi.1005948 |
0.687 |
|
| 2018 |
Prabhu VV, Madhukar N, Kline CLB, Tarapore R, El-Deiry WS, Rucker J, Doranz B, Doherty F, VanEngelenburg A, Durrant J, Benes C, Deacon S, Charter N, Free RB, Oster W, ... Sibley D, et al. Abstract 3857: Selective targeting of dopamine receptor dysregulation in high grade gliomas with imipridone ONC201 Cancer Research. 78: 3857-3857. DOI: 10.1158/1538-7445.Am2018-3857 |
0.794 |
|
| 2018 |
Madhukar NS, Prabhu VV, Anantharaman L, Sulli C, Davidson E, Deacon S, Rucker J, Charter N, Doranz B, Oster W, Elemento O, Free RB, Sibley D, Allen JE. Abstract B130: Differentiated pharmacology of the imipridone ONC201: the first selective DRD2/3 antagonist in clinical oncology Molecular Cancer Therapeutics. 17. DOI: 10.1158/1535-7163.Targ-17-B130 |
0.775 |
|
| 2018 |
Cuoco CA, Free RB, Willette BK, Day MM, Lane JR, Allen JE, Sibley DR. Characterization of the novel anti-cancer therapeutic ONC201 and related analogs as non-competitive antagonists of the D2 dopamine receptor The Faseb Journal. 32. DOI: 10.1096/Fasebj.2018.32.1_Supplement.827.10 |
0.794 |
|
| 2018 |
Prabhu VV, Madhukar N, Tarapore R, Garnett M, McDermott U, Benes C, Anantharaman L, Charter N, Deacon S, VanEngelenburg A, Rucker J, Doranz B, Rusert J, Wechsler-Reya R, Elemento O, ... ... Sibley D, et al. EXTH-17. SELECTIVE, NON-COMPETITIVE DRD2/3 ANTAGONISM BY IMIPRIDONE ONC206 IS EFFECTIVE IN TUMORS WITH DOPAMINE RECEPTOR DYSREGULATION Neuro-Oncology. 20: vi88-vi88. DOI: 10.1093/Neuonc/Noy148.366 |
0.744 |
|
| 2018 |
Vijay Prabhu V, Madhukar N, Anantharaman L, Sulli C, Davidson E, Deacon S, Tarapore R, Rucker J, Charter N, Doranz B, Oster W, Stogniew M, Elemento O, Free RB, Sibley D, et al. DDIS-12. ONC201: THE FIRST SELECTIVE, NON-COMPETITIVE DRD2/3 ANTAGONIST FOR CLINICAL NEURO-ONCOLOGY Neuro-Oncology. 20: vi71-vi71. DOI: 10.1093/Neuonc/Noy148.291 |
0.639 |
|
| 2017 |
Carr GV, Maltese F, Sibley DR, Weinberger DR, Papaleo F. The Dopamine D5 Receptor Is Involved in Working Memory. Frontiers in Pharmacology. 8: 666. PMID 29056909 DOI: 10.3389/Fphar.2017.00666 |
0.5 |
|
| 2017 |
Moritz AE, Benjamin Free R, Sibley DR. Advances and challenges in the search for D2 and D3 dopamine receptor-selective compounds. Cellular Signalling. PMID 28716664 DOI: 10.1016/J.Cellsig.2017.07.003 |
0.815 |
|
| 2017 |
Kumar V, Moritz AE, Keck TM, Bonifazi A, Ellenberger MP, Sibley CD, Free RB, Shi L, Lane JR, Sibley DR, Newman AH. Synthesis and Pharmacological Characterization of Novel trans-Cyclopropylmethyl-Linked Bivalent Ligands That Exhibit Selectivity and Allosteric Pharmacology at the Dopamine D3 Receptor (D3R). Journal of Medicinal Chemistry. PMID 28186762 DOI: 10.1021/Acs.Jmedchem.6B01688 |
0.86 |
|
| 2017 |
Madhukar N, Prabhu VV, Anantharaman L, Sulli C, Davidson E, Deacon S, Tarapore R, Rucker J, Charter N, Doranz B, Oster W, Elemento O, Free RB, Sibley D, Allen JE. EXTH-43. DIFFERENTIATED PHARMACOLOGY OF THE IMIPRIDONE ONC201, THE FIRST SELECTIVE DRD2/3 ANTAGONIST IN CLINICAL NEURO-ONCOLOGY Neuro-Oncology. 19: vi81-vi82. DOI: 10.1093/Neuonc/Nox168.335 |
0.783 |
|
| 2016 |
Zou MF, Keck TM, Kumar V, Donthamsetti P, Michino M, Burzynski C, Schweppe C, Bonifazi A, Free RB, Sibley DR, Janowsky A, Shi L, Javitch JA, Newman AH. Novel Analogues of (R)-5-(Methylamino)-5,6-dihydro-4H-imidazo[4,5,1-ij]quinolin-2(1H)-one (Sumanirole) Provide Clues to Dopamine D2/D3 Receptor Agonist Selectivity. Journal of Medicinal Chemistry. PMID 27035329 DOI: 10.1021/Acs.Jmedchem.5B01612 |
0.731 |
|
| 2016 |
Luderman KD, Conroy JL, Free RB, Southall NT, Ferrer M, Aubé J, Frankowski KJ, Sibley DR. Structurally Diverse Positive Allosteric Modulators of the D1 Dopamine Receptor Potentiate G‐Protein and β‐Arrestin‐Mediated Signaling The Faseb Journal. 30. DOI: 10.1096/Fasebj.30.1_Supplement.931.9 |
0.845 |
|
| 2015 |
Michino M, Free RB, Doyle TB, Sibley DR, Shi L. Structural basis for Na(+)-sensitivity in dopamine D2 and D3 receptors. Chemical Communications (Cambridge, England). 51: 8618-21. PMID 25896577 DOI: 10.1039/C5Cc02204E |
0.779 |
|
| 2015 |
Dix AV, Conroy JL, George Rosenker KM, Sibley DR, Appella DH. PNA-Based Multivalent Scaffolds Activate the Dopamine D2 Receptor. Acs Medicinal Chemistry Letters. 6: 425-9. PMID 25893044 DOI: 10.1021/Ml500478M |
0.618 |
|
| 2015 |
Yang S, Yang Y, Yu P, Yang J, Jiang X, Villar VA, Sibley DR, Jose PA, Zeng C. Dopamine D1 and D5 receptors differentially regulate oxidative stress through paraoxonase 2 in kidney cells. Free Radical Research. 49: 397-410. PMID 25740199 DOI: 10.3109/10715762.2015.1006215 |
0.388 |
|
| 2015 |
Conroy JL, Free RB, Sibley DR. Identification of G protein-biased agonists that fail to recruit β-arrestin or promote internalization of the D1 dopamine receptor. Acs Chemical Neuroscience. 6: 681-92. PMID 25660762 DOI: 10.1021/Acschemneuro.5B00020 |
0.772 |
|
| 2015 |
Frederick AL, Yano H, Trifilieff P, Vishwasrao HD, Biezonski D, Mészáros J, Urizar E, Sibley DR, Kellendonk C, Sonntag KC, Graham DL, Colbran RJ, Stanwood GD, Javitch JA. Evidence against dopamine D1/D2 receptor heteromers. Molecular Psychiatry. PMID 25560761 DOI: 10.1038/Mp.2014.166 |
0.602 |
|
| 2015 |
Meade JA, Free RB, Miller NR, Chun LS, Doyle TB, Moritz AE, Conroy JL, Watts VJ, Sibley DR. (-)-Stepholidine is a potent pan-dopamine receptor antagonist of both G protein- and β-arrestin-mediated signaling. Psychopharmacology. 232: 917-30. PMID 25231919 DOI: 10.1007/S00213-014-3726-8 |
0.884 |
|
| 2015 |
Chun LS, Benjamin Free R, Sibley DR. Calcium and phospholipase Cβ signaling through dopamine receptors Neuromethods. 96: 251-263. DOI: 10.1007/978-1-4939-2196-6_14 |
0.399 |
|
| 2014 |
Furman CA, Roof RA, Moritz AE, Miller BN, Doyle TB, Free RB, Banala AK, Paul NM, Kumar V, Sibley CD, Newman AH, Sibley DR. Investigation of the binding and functional properties of extended length D3 dopamine receptor-selective antagonists. European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology. PMID 25583363 DOI: 10.1016/J.Euroneuro.2014.11.013 |
0.876 |
|
| 2014 |
Ennis RC, Asico LD, Armando I, Yang J, Feranil JB, Jurgens JA, Escano CS, Yu P, Wang X, Sibley DR, Jose PA, Villar VA. Dopamine Dâ‚-like receptors regulate the αâ‚A-adrenergic receptor in human renal proximal tubule cells and Dâ‚-like dopamine receptor knockout mice. American Journal of Physiology. Renal Physiology. 307: F1238-48. PMID 25339698 DOI: 10.1152/Ajprenal.00119.2014 |
0.545 |
|
| 2014 |
Free RB, Chun LS, Moritz AE, Miller BN, Doyle TB, Conroy JL, Padron A, Meade JA, Xiao J, Hu X, Dulcey AE, Han Y, Duan L, Titus S, Bryant-Genevier M, ... ... Sibley DR, et al. Discovery and characterization of a G protein-biased agonist that inhibits β-arrestin recruitment to the D2 dopamine receptor. Molecular Pharmacology. 86: 96-105. PMID 24755247 DOI: 10.1124/Mol.113.090563 |
0.874 |
|
| 2014 |
Xiao J, Free RB, Barnaeva E, Conroy JL, Doyle T, Miller B, Bryant-Genevier M, Taylor MK, Hu X, Dulcey AE, Southall N, Ferrer M, Titus S, Zheng W, Sibley DR, et al. Discovery, optimization, and characterization of novel D2 dopamine receptor selective antagonists. Journal of Medicinal Chemistry. 57: 3450-63. PMID 24666157 DOI: 10.1021/Jm500126S |
0.742 |
|
| 2013 |
Chun LS, Free RB, Doyle TB, Huang XP, Rankin ML, Sibley DR. D1-D2 dopamine receptor synergy promotes calcium signaling via multiple mechanisms. Molecular Pharmacology. 84: 190-200. PMID 23680635 DOI: 10.1124/Mol.113.085175 |
0.756 |
|
| 2013 |
Bergman J, Roof RA, Furman CA, Conroy JL, Mello NK, Sibley DR, Skolnick P. Modification of cocaine self-administration by buspirone (buspar®): potential involvement of D3 and D4 dopamine receptors. The International Journal of Neuropsychopharmacology / Official Scientific Journal of the Collegium Internationale Neuropsychopharmacologicum (Cinp). 16: 445-58. PMID 22827916 DOI: 10.1017/S1461145712000661 |
0.531 |
|
| 2013 |
Free RB, Conroy JL, Roof RA, Doyle T, Han Y, Donthamsetti P, Javitch JA, Southall N, Emmitte K, Lindsley C, Ferrer M, Sibley DR. High-Throughput Screening for Modulators of the D2 Dopamine Receptor Yields Unique and Selective Pharmacological Chemotypes Catecholamine Research in the 21st Century: Abstracts and Graphical Abstracts, 10th International Catecholamine Symposium, 2012. 115. DOI: 10.1016/B978-0-12-800044-1.00101-X |
0.746 |
|
| 2013 |
Conroy JL, Free RB, Doyle TB, Sibley DR. Identification of Substituted Benzazepines as Functionally Selective Ligands of the D1 Dopamine Receptor Catecholamine Research in the 21st Century: Abstracts and Graphical Abstracts, 10th International Catecholamine Symposium, 2012. 113. DOI: 10.1016/B978-0-12-800044-1.00099-4 |
0.763 |
|
| 2013 |
Chun LS, Free RB, Doyle TB, Huang XP, Sibley DR. Investigation of the D1-D2 heteromer: Pharmacology, subunit composition, and mechanisms of signaling Catecholamine Research in the 21st Century: Abstracts and Graphical Abstracts, 10th International Catecholamine Symposium, 2012. 106. DOI: 10.1016/B978-0-12-800044-1.00092-1 |
0.628 |
|
| 2013 |
Sibley DR, Free RB, Namkung Y, Lisa A. Sorting NEXIN-25 Interacts with D1 and D2Dopamine Receptors to Regulate Receptor Expression and Signaling Catecholamine Research in the 21st Century: Abstracts and Graphical Abstracts, 10th International Catecholamine Symposium, 2012. 96-97. DOI: 10.1016/B978-0-12-800044-1.00083-0 |
0.752 |
|
| 2012 |
Newman AH, Blaylock BL, Nader MA, Bergman J, Sibley DR, Skolnick P. Medication discovery for addiction: translating the dopamine D3 receptor hypothesis. Biochemical Pharmacology. 84: 882-90. PMID 22781742 DOI: 10.1016/J.Bcp.2012.06.023 |
0.448 |
|
| 2012 |
Maison SF, Liu XP, Eatock RA, Sibley DR, Grandy DK, Liberman MC. Dopaminergic signaling in the cochlea: receptor expression patterns and deletion phenotypes. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 32: 344-55. PMID 22219295 DOI: 10.1523/Jneurosci.4720-11.2012 |
0.488 |
|
| 2012 |
Skinbjerg M, Sibley DR, Javitch JA, Abi-Dargham A. Imaging the high-affinity state of the dopamine D2 receptor in vivo: fact or fiction? Biochemical Pharmacology. 83: 193-8. PMID 21945484 DOI: 10.1016/J.Bcp.2011.09.008 |
0.512 |
|
| 2011 |
Banala AK, Levy BA, Khatri SS, Furman CA, Roof RA, Mishra Y, Griffin SA, Sibley DR, Luedtke RR, Newman AH. N-(3-fluoro-4-(4-(2-methoxy or 2,3-dichlorophenyl)piperazine-1-yl)butyl)arylcarboxamides as selective dopamine D3 receptor ligands: critical role of the carboxamide linker for D3 receptor selectivity. Journal of Medicinal Chemistry. 54: 3581-94. PMID 21495689 DOI: 10.1021/Jm200288R |
0.575 |
|
| 2011 |
Reichart DL, Hinkle RT, Lefever FR, Dolan ET, Dietrich JA, Sibley DR, Isfort RJ. Activation of the dopamine 1 and dopamine 5 receptors increase skeletal muscle mass and force production under non-atrophying and atrophying conditions. Bmc Musculoskeletal Disorders. 12: 27. PMID 21269506 DOI: 10.1186/1471-2474-12-27 |
0.349 |
|
| 2011 |
Kramer PF, Christensen CH, Hazelwood LA, Dobi A, Bock R, Sibley DR, Mateo Y, Alvarez VA. Dopamine D2 receptor overexpression alters behavior and physiology in Drd2-EGFP mice. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 31: 126-32. PMID 21209197 DOI: 10.1523/Jneurosci.4287-10.2011 |
0.791 |
|
| 2011 |
Asico L, Zhang X, Jiang J, Cabrera D, Escano CS, Sibley DR, Wang X, Yang Y, Mannon R, Jones JE, Armando I, Jose PA. Lack of renal dopamine D5 receptors promotes hypertension. Journal of the American Society of Nephrology : Jasn. 22: 82-9. PMID 21051739 DOI: 10.1681/ASN.2010050533 |
0.752 |
|
| 2011 |
Sibley D, Hazelwood L, Roof R, Free R, Han Y, Javitch J. Membrane lipid rafts are required for D2 dopamine receptor signaling European Psychiatry. 26: 910-910. DOI: 10.1016/S0924-9338(11)72615-3 |
0.769 |
|
| 2011 |
Neve K, Sibley DR. D2-like dopamine receptors Xpharm: the Comprehensive Pharmacology Reference. 1-4. DOI: 10.1016/B978-008055232-3.60156-4 |
0.554 |
|
| 2011 |
Neve K, Sibley DR. D3 dopamine receptor Xpharm: the Comprehensive Pharmacology Reference. 1-13. DOI: 10.1016/B978-008055232-3.60154-0 |
0.552 |
|
| 2011 |
Sibley DR, Neve K. D1 dopamine receptor Xpharm: the Comprehensive Pharmacology Reference. 1-13. DOI: 10.1016/B978-008055232-3.60153-9 |
0.552 |
|
| 2011 |
Sibley DR, Neve K. D1-like dopamine receptors Xpharm: the Comprehensive Pharmacology Reference. 1-4. DOI: 10.1016/B978-008055232-3.60152-7 |
0.554 |
|
| 2010 |
Rankin ML, Sibley DR. Constitutive phosphorylation by protein kinase C regulates D1 dopamine receptor signaling. Journal of Neurochemistry. 115: 1655-67. PMID 20969574 DOI: 10.1111/j.1471-4159.2010.07074.x |
0.536 |
|
| 2010 |
Wang X, Luo Y, Escano CS, Yang Z, Asico L, Li H, Jones JE, Armando I, Lu Q, Sibley DR, Eisner GM, Jose PA. Upregulation of renal sodium transporters in D5 dopamine receptor-deficient mice. Hypertension. 55: 1431-7. PMID 20404220 DOI: 10.1161/Hypertensionaha.109.148643 |
0.384 |
|
| 2010 |
Rex EB, Rankin ML, Yang Y, Lu Q, Gerfen CR, Jose PA, Sibley DR. Identification of RanBP 9/10 as interacting partners for protein kinase C (PKC) gamma/delta and the D1 dopamine receptor: regulation of PKC-mediated receptor phosphorylation. Molecular Pharmacology. 78: 69-80. PMID 20395553 DOI: 10.1124/Mol.110.063727 |
0.564 |
|
| 2010 |
Skinbjerg M, Seneca N, Liow JS, Hong J, Weinshenker D, Pike VW, Halldin C, Sibley DR, Innis RB. Dopamine beta-hydroxylase-deficient mice have normal densities of D(2) dopamine receptors in the high-affinity state based on in vivo PET imaging and in vitro radioligand binding. Synapse (New York, N.Y.). 64: 699-703. PMID 20336622 DOI: 10.1002/Syn.20781 |
0.566 |
|
| 2010 |
Skinbjerg M, Liow JS, Seneca N, Hong J, Lu S, Thorsell A, Heilig M, Pike VW, Halldin C, Sibley DR, Innis RB. D2 dopamine receptor internalization prolongs the decrease of radioligand binding after amphetamine: a PET study in a receptor internalization-deficient mouse model. Neuroimage. 50: 1402-7. PMID 20097293 DOI: 10.1016/J.Neuroimage.2010.01.055 |
0.584 |
|
| 2010 |
Rankin ML, Hazelwood LA, Free RB, Namkung Y, Rex EB, Roof RA, Sibley DR. Molecular Pharmacology of the Dopamine Receptors Dopamine Handbook. DOI: 10.1093/acprof:oso/9780195373035.003.0006 |
0.865 |
|
| 2009 |
Namkung Y, Dipace C, Urizar E, Javitch JA, Sibley DR. G protein-coupled receptor kinase-2 constitutively regulates D2 dopamine receptor expression and signaling independently of receptor phosphorylation. The Journal of Biological Chemistry. 284: 34103-15. PMID 19815545 DOI: 10.1074/Jbc.M109.055707 |
0.607 |
|
| 2009 |
Namkung Y, Dipace C, Javitch JA, Sibley DR. G protein-coupled receptor kinase-mediated phosphorylation regulates post-endocytic trafficking of the D2 dopamine receptor. The Journal of Biological Chemistry. 284: 15038-51. PMID 19332542 DOI: 10.1074/Jbc.M900388200 |
0.609 |
|
| 2009 |
Skinbjerg M, Ariano MA, Thorsell A, Heilig M, Halldin C, Innis RB, Sibley DR. Arrestin3 mediates D(2) dopamine receptor internalization. Synapse (New York, N.Y.). 63: 621-4. PMID 19309759 DOI: 10.1002/Syn.20636 |
0.522 |
|
| 2009 |
Skinbjerg M, Namkung Y, Halldin C, Innis RB, Sibley DR. Pharmacological characterization of 2-methoxy-N-propylnorapomorphine's interactions with D2 and D3 dopamine receptors. Synapse (New York, N.Y.). 63: 462-75. PMID 19217026 DOI: 10.1002/Syn.20626 |
0.576 |
|
| 2009 |
Free RB, Hazelwood LA, Sibley DR. Identifying novel protein-protein interactions using co-immunoprecipitation and mass spectroscopy. Current Protocols in Neuroscience / Editorial Board, Jacqueline N. Crawley ... [Et Al.]. Unit 5.28. PMID 19170023 DOI: 10.1002/0471142301.Ns0528S46 |
0.792 |
|
| 2009 |
Sahu A, Tyeryar KR, Vongtau HO, Sibley DR, Undieh AS. D5 dopamine receptors are required for dopaminergic activation of phospholipase C. Molecular Pharmacology. 75: 447-53. PMID 19047479 DOI: 10.1124/mol.108.053017 |
0.626 |
|
| 2008 |
Hazelwood LA, Free RB, Cabrera DM, Skinbjerg M, Sibley DR. Reciprocal modulation of function between the D1 and D2 dopamine receptors and the Na+,K+-ATPase. The Journal of Biological Chemistry. 283: 36441-53. PMID 18984584 DOI: 10.1074/Jbc.M805520200 |
0.856 |
|
| 2008 |
Argilli E, Sibley DR, Malenka RC, England PM, Bonci A. Mechanism and time course of cocaine-induced long-term potentiation in the ventral tegmental area. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 28: 9092-100. PMID 18784289 DOI: 10.1523/Jneurosci.1001-08.2008 |
0.359 |
|
| 2008 |
Seneca N, Zoghbi SS, Skinbjerg M, Liow JS, Hong J, Sibley DR, Pike VW, Halldin C, Innis RB. Occupancy of dopamine D2/3 receptors in rat brain by endogenous dopamine measured with the agonist positron emission tomography radioligand [11C]MNPA. Synapse (New York, N.Y.). 62: 756-63. PMID 18651641 DOI: 10.1002/Syn.20549 |
0.559 |
|
| 2008 |
Li H, Armando I, Yu P, Escano C, Mueller SC, Asico L, Pascua A, Lu Q, Wang X, Villar VA, Jones JE, Wang Z, Periasamy A, Lau YS, Soares-da-Silva P, ... ... Sibley DR, et al. Dopamine 5 receptor mediates Ang II type 1 receptor degradation via a ubiquitin-proteasome pathway in mice and human cells. The Journal of Clinical Investigation. 118: 2180-9. PMID 18464932 DOI: 10.1172/Jci33637 |
0.467 |
|
| 2008 |
O'Sullivan GJ, Dunleavy M, Hakansson K, Clementi M, Kinsella A, Croke DT, Drago J, Fienberg AA, Greengard P, Sibley DR, Fisone G, Henshall DC, Waddington JL. Dopamine D1 vs D5 receptor-dependent induction of seizures in relation to DARPP-32, ERK1/2 and GluR1-AMPA signalling. Neuropharmacology. 54: 1051-61. PMID 18367215 DOI: 10.1016/J.Neuropharm.2008.02.011 |
0.452 |
|
| 2008 |
Kim OJ, Ariano MA, Namkung Y, Marinec P, Kim E, Han J, Sibley DR. D2 dopamine receptor expression and trafficking is regulated through direct interactions with ZIP. Journal of Neurochemistry. 106: 83-95. PMID 18346199 DOI: 10.1111/j.1471-4159.2008.05348.x |
0.512 |
|
| 2008 |
Rex EB, Rankin ML, Ariano MA, Sibley DR. Ethanol regulation of D(1) dopamine receptor signaling is mediated by protein kinase C in an isozyme-specific manner. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 33: 2900-11. PMID 18288091 DOI: 10.1038/npp.2008.16 |
0.5 |
|
| 2008 |
Li H, Armando I, Yu P, Escano C, Mueller SC, Asico L, Pascua A, Lu Q, Wang X, Villar VAM, Jones JE, Wang Z, Periasamy A, Lau YS, Soares-Da-Silva P, ... ... Sibley DR, et al. Dopamine 5 receptor mediates Ang II type 1 receptor degradation via a ubiquitin-proteasome pathway in mice and human cells (Journal of Clinical Investigation (2008) 118, (2180-2189) DOI: 10.1172/JCI33637) Journal of Clinical Investigation. 118: 2986. DOI: 10.1172/JCI33637C1 |
0.419 |
|
| 2008 |
Skinbjerg M, Namkung Y, Halldin C, Innis R, Sibley D. Pharmacological characterization of the interactions of 2-methoxy-N-propylnorapomorphine (MNPA) with D2 and D3 dopamine receptors Neuroimage. 41: T140. DOI: 10.1016/j.neuroimage.2008.04.108 |
0.568 |
|
| 2007 |
Free RB, Hazelwood LA, Cabrera DM, Spalding HN, Namkung Y, Rankin ML, Sibley DR. D1 and D2 dopamine receptor expression is regulated by direct interaction with the chaperone protein calnexin. The Journal of Biological Chemistry. 282: 21285-300. PMID 17395585 DOI: 10.1074/Jbc.M701555200 |
0.856 |
|
| 2007 |
Wang Z, Armando I, Asico LD, Escano C, Wang X, Lu Q, Felder RA, Schnackenberg CG, Sibley DR, Eisner GM, Jose PA. The elevated blood pressure of human GRK4gamma A142V transgenic mice is not associated with increased ROS production. American Journal of Physiology. Heart and Circulatory Physiology. 292: H2083-92. PMID 17259440 DOI: 10.1152/Ajpheart.00944.2006 |
0.349 |
|
| 2007 |
Hernández-Echeagaray E, Cepeda C, Ariano MA, Lobo MK, Sibley DR, Levine MS. Dopamine reduction of GABA currents in striatal medium-sized spiny neurons is mediated principally by the D(1) receptor subtype. Neurochemical Research. 32: 229-40. PMID 17031565 DOI: 10.1007/S11064-006-9141-8 |
0.534 |
|
| 2007 |
Free RB, Hazelwood LA, Spalding HN, Cabrera DM, Sibley DR. Sorting nexin‐25, a novel member of the dopamine receptor signalplex, up‐regulates D
1
and D
2
dopamine receptor expression in HEK293 cells The Faseb Journal. 21. DOI: 10.1096/Fasebj.21.5.A423-D |
0.87 |
|
| 2007 |
Hazelwood LA, Free RB, Cabrera DM, Neiman J, Quinn S, Sibley DR. Reciprocal modulation of function between the D
1
and D
2
dopamine receptors and the Na
+
/K
+
‐ATPase, a novel member of the dopamine receptor signalplex The Faseb Journal. 21. DOI: 10.1096/Fasebj.21.5.A423 |
0.863 |
|
| 2006 |
Tomiyama K, Makihara Y, Yamamoto H, O'Sullivan G, Nally RE, Tighe O, Kinsella A, Fienberg AA, Grandy DK, Sibley DR, Croke DT, Koshikawa N, Waddington JL. Disruption of orofacial movement topographies in congenic mutants with dopamine D5 but not D4 receptor or DARPP-32 transduction 'knockout'. European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology. 16: 437-45. PMID 16413758 DOI: 10.1016/j.euroneuro.2005.11.012 |
0.502 |
|
| 2006 |
Yang Z, Asico LD, Yu P, Wang Z, Jones JE, Escano CS, Wang X, Quinn MT, Sibley DR, Romero GG, Felder RA, Jose PA. D5 dopamine receptor regulation of reactive oxygen species production, NADPH oxidase, and blood pressure. American Journal of Physiology. Regulatory, Integrative and Comparative Physiology. 290: R96-R104. PMID 16352863 DOI: 10.1152/Ajpregu.00434.2005 |
0.519 |
|
| 2006 |
Rankin ML, Marinec PS, Cabrera DM, Wang Z, Jose PA, Sibley DR. The D1 dopamine receptor is constitutively phosphorylated by G protein-coupled receptor kinase 4. Molecular Pharmacology. 69: 759-69. PMID 16338988 DOI: 10.1124/Mol.105.019901 |
0.839 |
|
| 2005 |
Zeng C, Yang Z, Wang Z, Jones J, Wang X, Altea J, Mangrum AJ, Hopfer U, Sibley DR, Eisner GM, Felder RA, Jose PA. Interaction of angiotensin II type 1 and D5 dopamine receptors in renal proximal tubule cells. Hypertension. 45: 804-10. PMID 15699451 DOI: 10.1161/01.Hyp.0000155212.33212.99 |
0.559 |
|
| 2005 |
Kudwa AE, Dominguez-Salazar E, Cabrera DM, Sibley DR, Rissman EF. Dopamine D5 receptor modulates male and female sexual behavior in mice. Psychopharmacology. 180: 206-14. PMID 15696326 DOI: 10.1007/s00213-005-2150-5 |
0.724 |
|
| 2005 |
O'Sullivan GJ, Kinsella A, Sibley DR, Tighe O, Croke DT, Waddington JL. Ethological resolution of behavioural topography and D1-like versus D2-like agonist responses in congenic D5 dopamine receptor mutants: identification of D5:D2-like interactions. Synapse (New York, N.Y.). 55: 201-11. PMID 15668951 DOI: 10.1002/syn.20107 |
0.412 |
|
| 2005 |
Yang Z, Asico LD, Yu P, Wang Z, Jones JE, Bai RK, Sibley DR, Felder RA, Jose PA. D5 dopamine receptor regulation of phospholipase D. American Journal of Physiology. Heart and Circulatory Physiology. 288: H55-61. PMID 15598876 DOI: 10.1152/Ajpheart.00627.2004 |
0.535 |
|
| 2005 |
YANG Z, ASICO L, YU P, WANG Z, JONES J, FELDER R, SIBLEY D, JOSE P. Hypertension and PLD2 regulation by D dopamine receptor American Journal of Hypertension. 18: A165-A165. DOI: 10.1016/J.Amjhyper.2005.03.457 |
0.598 |
|
| 2004 |
Holmes A, Lachowicz JE, Sibley DR. Phenotypic analysis of dopamine receptor knockout mice; recent insights into the functional specificity of dopamine receptor subtypes. Neuropharmacology. 47: 1117-34. PMID 15567422 DOI: 10.1016/j.neuropharm.2004.07.034 |
0.576 |
|
| 2004 |
Yang Z, Sibley DR, Jose PA. D5 dopamine receptor knockout mice and hypertension. Journal of Receptor and Signal Transduction Research. 24: 149-64. PMID 15521360 DOI: 10.1081/Rrs-200029971 |
0.591 |
|
| 2004 |
O'Sullivan GJ, Clifford JJ, Tomiyama K, Koshikawa N, Drago J, Sibley DR, Croke DT, Waddington JL. D1-like dopamine receptor-mediated function in congenic mutants with D1 vs. D5 receptor "knockout". Journal of Receptor and Signal Transduction Research. 24: 107-16. PMID 15521357 DOI: 10.1081/RRS-200032078 |
0.534 |
|
| 2004 |
Namkung Y, Sibley DR. Protein kinase C mediates phosphorylation, desensitization, and trafficking of the D2 dopamine receptor. The Journal of Biological Chemistry. 279: 49533-41. PMID 15347675 DOI: 10.1074/jbc.M408319200 |
0.515 |
|
| 2004 |
Laplante F, Sibley DR, Quirion R. Reduction in acetylcholine release in the hippocampus of dopamine D5 receptor-deficient mice. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 29: 1620-7. PMID 15100705 DOI: 10.1038/Sj.Npp.1300467 |
0.557 |
|
| 2004 |
Kim OJ, Gardner BR, Williams DB, Marinec PS, Cabrera DM, Peters JD, Mak CC, Kim KM, Sibley DR. The role of phosphorylation in D1 dopamine receptor desensitization: evidence for a novel mechanism of arrestin association. The Journal of Biological Chemistry. 279: 7999-8010. PMID 14660631 DOI: 10.1074/jbc.M308281200 |
0.817 |
|
| 2004 |
O'Sullivan GJ, Croke DT, Tighe O, Kinsella A, Grandy DK, Low MJ, Rubinstein M, Sibley DR, Waddington JL. P.2.27 Topographical evaluation of spontaneous and agonist-induced behaviour in mutants with congenic dopamine D4 versus D5 receptor knockout European Neuropsychopharmacology. 14. DOI: 10.1016/S0924-977X(04)90050-8 |
0.57 |
|
| 2003 |
Shapiro DA, Renock S, Arrington E, Chiodo LA, Liu LX, Sibley DR, Roth BL, Mailman R. Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 28: 1400-11. PMID 12784105 DOI: 10.1038/sj.npp.1300203 |
0.514 |
|
| 2003 |
Elliot EE, Sibley DR, Katz JL. Locomotor and discriminative-stimulus effects of cocaine in dopamine D5 receptor knockout mice. Psychopharmacology. 169: 161-8. PMID 12768268 DOI: 10.1007/S00213-003-1494-Y |
0.434 |
|
| 2003 |
Schetz JA, Kim OJ, Sibley DR. Pharmacological characterization of mammalian D1 and D2 dopamine receptors expressed in Drosophila Schneider-2 cells. Journal of Receptor and Signal Transduction Research. 23: 99-109. PMID 12680592 DOI: 10.1081/RRS-120018763 |
0.64 |
|
| 2002 |
Hollon TR, Bek MJ, Lachowicz JE, Ariano MA, Mezey E, Ramachandran R, Wersinger SR, Soares-da-Silva P, Liu ZF, Grinberg A, Drago J, Young WS, Westphal H, Jose PA, Sibley DR. Mice lacking D5 dopamine receptors have increased sympathetic tone and are hypertensive. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 22: 10801-10. PMID 12486173 DOI: 10.1523/Jneurosci.22-24-10801.2002 |
0.601 |
|
| 2002 |
Kim OJ, Ariano MA, Lazzarini RA, Levine MS, Sibley DR. Neurofilament-M interacts with the D1 dopamine receptor to regulate cell surface expression and desensitization. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 22: 5920-30. PMID 12122054 DOI: 10.1523/Jneurosci.22-14-05920.2002 |
0.554 |
|
| 2002 |
Ariano MA, Aronin N, Difiglia M, Tagle DA, Sibley DR, Leavitt BR, Hayden MR, Levine MS. Striatal neurochemical changes in transgenic models of Huntington's disease. Journal of Neuroscience Research. 68: 716-29. PMID 12111832 DOI: 10.1002/Jnr.10272 |
0.571 |
|
| 2001 |
Hunyady B, Palkovits M, Mózsik G, Molnár J, Fehér K, Tóth Z, Zólyomi A, Szalayova I, Key S, Sibley DR, Mezey E. Susceptibility of dopamine D5 receptor targeted mice to cysteamine. Journal of Physiology, Paris. 95: 147-51. PMID 11595429 DOI: 10.1016/S0928-4257(01)00019-5 |
0.514 |
|
| 2001 |
Holmes A, Hollon TR, Gleason TC, Liu Z, Dreiling J, Sibley DR, Crawley JN. Behavioral characterization of dopamine D5 receptor null mutant mice. Behavioral Neuroscience. 115: 1129-44. PMID 11584926 DOI: 10.1037/0735-7044.115.5.1129 |
0.472 |
|
| 2001 |
Gardner B, Liu ZF, Jiang D, Sibley DR. The role of phosphorylation/dephosphorylation in agonist-induced desensitization of D1 dopamine receptor function: evidence for a novel pathway for receptor dephosphorylation. Molecular Pharmacology. 59: 310-21. PMID 11160868 DOI: 10.1124/Mol.59.2.310 |
0.647 |
|
| 2001 |
Schetz JA, Sibley DR. The binding-site crevice of the D4 dopamine receptor is coupled to three distinct sites of allosteric modulation. The Journal of Pharmacology and Experimental Therapeutics. 296: 359-63. PMID 11160618 |
0.468 |
|
| 2001 |
Holmes A, Hollon TR, Gleason TC, Liu Z, Dreiling J, Sibley DR, Crawley JN. Behavioral characterization of dopamine D-sub-5 receptor null mutant mice. Behavioral Neuroscience. 115: 1129-1144. DOI: 10.1037//0735-7044.115.5.1129 |
0.519 |
|
| 2000 |
Ventura AL, Sibley DR. Altered regulation of the D(1) dopamine receptor in mutant Chinese hamster ovary cells deficient in cyclic AMP-dependent protein kinase activity. The Journal of Pharmacology and Experimental Therapeutics. 293: 426-34. PMID 10773012 |
0.452 |
|
| 2000 |
Schetz JA, Sibley DR. Tandem sulfur-containing amino acids are epicritical determinants of dopamine D(2) receptor pharmacology. European Journal of Pharmacology. 388: R5-7. PMID 10666514 DOI: 10.1016/S0014-2999(99)00867-5 |
0.498 |
|
| 2000 |
Schetz JA, Benjamin PS, Sibley DR. Nonconserved residues in the second transmembrane-spanning domain of the D(4) dopamine receptor are molecular determinants of D(4)-selective pharmacology. Molecular Pharmacology. 57: 144-52. PMID 10617689 |
0.487 |
|
| 2000 |
Bek MJ, Asico LD, Eisner GM, Sibley DR, Jose PA. Non-N-Methyl D-Aspartate Receptors Are Involved in the Hypertension of D5 Dopamine Receptor Knockout Mice. Hypertension. 36: 726-726. DOI: 10.1161/01.Hyp.36.Suppl_1.726-D |
0.44 |
|
| 1999 |
El-Ghundi M, Fletcher PJ, Drago J, Sibley DR, O'Dowd BF, George SR. Spatial learning deficit in dopamine D(1) receptor knockout mice. European Journal of Pharmacology. 383: 95-106. PMID 10585522 DOI: 10.1016/S0014-2999(99)00573-7 |
0.678 |
|
| 1999 |
Cepeda C, Li Z, Cromwell HC, Altemus KL, Crawford CA, Nansen EA, Ariano MA, Sibley DR, Peacock WJ, Mathern GW, Levine MS. Electrophysiological and morphological analyses of cortical neurons obtained from children with catastrophic epilepsy: dopamine receptor modulation of glutamatergic responses. Developmental Neuroscience. 21: 223-35. PMID 10575246 DOI: 10.1159/000017402 |
0.573 |
|
| 1999 |
Clifford JJ, Tighe O, Croke DT, Kinsella A, Sibley DR, Drago J, Waddington JL. Conservation of behavioural topography to dopamine D1-like receptor agonists in mutant mice lacking the D1A receptor implicates a D1-like receptor not coupled to adenylyl cyclase. Neuroscience. 93: 1483-9. PMID 10501473 DOI: 10.1016/S0306-4522(99)00297-3 |
0.595 |
|
| 1999 |
Jiang D, Sibley DR. Regulation of D(1) dopamine receptors with mutations of protein kinase phosphorylation sites: attenuation of the rate of agonist-induced desensitization. Molecular Pharmacology. 56: 675-83. PMID 10496949 |
0.537 |
|
| 1999 |
Sibley DR. New insights into dopaminergic receptor function using antisense and genetically altered animals. Annual Review of Pharmacology and Toxicology. 39: 313-41. PMID 10331087 DOI: 10.1146/annurev.pharmtox.39.1.313 |
0.575 |
|
| 1999 |
Lawler CP, Prioleau C, Lewis MM, Mak C, Jiang D, Schetz JA, Gonzalez AM, Sibley DR, Mailman RB. Interactions of the novel antipsychotic aripiprazole (OPC-14597) with dopamine and serotonin receptor subtypes. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 20: 612-27. PMID 10327430 DOI: 10.1016/S0893-133X(98)00099-2 |
0.642 |
|
| 1999 |
Schetz JA, Chu A, Sibley DR. Zinc modulates antagonist interactions with D2-like dopamine receptors through distinct molecular mechanisms. The Journal of Pharmacology and Experimental Therapeutics. 289: 956-64. PMID 10215675 |
0.548 |
|
| 1999 |
Cravchik A, Sibley DR, Gejman PV. Analysis of neuroleptic binding affinities and potencies for the different human D2 dopamine receptor missense variants. Pharmacogenetics. 9: 17-23. PMID 10208638 DOI: 10.1097/00008571-199902000-00003 |
0.604 |
|
| 1999 |
Liu LX, Burgess LH, Gonzalez AM, Sibley DR, Chiodo LA. D2S, D2L, D3, and D4 dopamine receptors couple to a voltage-dependent potassium current in N18TG2 x mesencephalon hybrid cell (MES-23.5) via distinct G proteins. Synapse (New York, N.Y.). 31: 108-18. PMID 10024007 DOI: 10.1002/(SICI)1098-2396(199902)31:2<108::AID-SYN3>3.0.CO;2-V |
0.582 |
|
| 1998 |
Clifford JJ, Tighe O, Croke DT, Sibley DR, Drago J, Waddington JL. Topographical evaluation of the phenotype of spontaneous behaviour in mice with targeted gene deletion of the D1A dopamine receptor: paradoxical elevation of grooming syntax. Neuropharmacology. 37: 1595-602. PMID 9886682 DOI: 10.1016/S0028-3908(98)00116-6 |
0.482 |
|
| 1998 |
El-Ghundi M, George SR, Drago J, Fletcher PJ, Fan T, Nguyen T, Liu C, Sibley DR, Westphal H, O'Dowd BF. Disruption of dopamine D1 receptor gene expression attenuates alcohol-seeking behavior. European Journal of Pharmacology. 353: 149-58. PMID 9726645 DOI: 10.1016/S0014-2999(98)00414-2 |
0.684 |
|
| 1998 |
Ariano MA, Drago J, Sibley DR, Levine MS. Striatal excitatory amino acid receptor subunit expression in the D1A-dopamine receptor-deficient mouse. Developmental Neuroscience. 20: 237-41. PMID 9691197 DOI: 10.1159/000017317 |
0.527 |
|
| 1998 |
Waddington JL, Deveney AM, Clifford J, Tighe O, Croke DT, Sibley DR, Drago J. Behavioral analysis of multiple D1-like dopamine receptor subtypes: new agents and studies in transgenic mice with D1A receptor knockout. Advances in Pharmacology (San Diego, Calif.). 42: 514-7. PMID 9327953 DOI: 10.1016/S1054-3589(08)60802-9 |
0.539 |
|
| 1998 |
Sibley DR, Ventura AL, Jiang D, Mak C. Regulation of the D1 dopamine receptor through cAMP-mediated pathways. Advances in Pharmacology (San Diego, Calif.). 42: 447-50. PMID 9327935 DOI: 10.1016/S1054-3589(08)60784-X |
0.614 |
|
| 1997 |
Ariano MA, Sortwell CE, Ray M, Altemus KL, Sibley DR, Levine MS. Agonist-induced morphologic decrease in cellular D1A dopamine receptor staining. Synapse (New York, N.Y.). 27: 313-21. PMID 9372554 DOI: 10.1002/(SICI)1098-2396(199712)27:4<313::AID-SYN5>3.0.CO;2-F |
0.582 |
|
| 1997 |
Lachowicz JE, Sibley DR. Molecular characteristics of mammalian dopamine receptors. Pharmacology & Toxicology. 81: 105-13. PMID 9335067 DOI: 10.1111/J.1600-0773.1997.Tb00039.X |
0.626 |
|
| 1997 |
Lachowicz JE, Sibley DR. Chimeric D2/D3 dopamine receptor coupling to adenylyl cyclase. Biochemical and Biophysical Research Communications. 237: 394-9. PMID 9268722 DOI: 10.1006/bbrc.1997.7146 |
0.619 |
|
| 1997 |
Ariano MA, Larson ER, Noblett KL, Sibley DR, Levine MS. Coexpression of striatal dopamine receptor subtypes and excitatory amino acid subunits. Synapse (New York, N.Y.). 26: 400-14. PMID 9215599 DOI: 10.1002/(Sici)1098-2396(199708)26:4<400::Aid-Syn8>3.0.Co;2-A |
0.573 |
|
| 1997 |
Schetz JA, Sibley DR. Zinc allosterically modulates antagonist binding to cloned D1 and D2 dopamine receptors. Journal of Neurochemistry. 68: 1990-7. PMID 9109525 DOI: 10.1046/J.1471-4159.1997.68051990.X |
0.615 |
|
| 1997 |
Ariano MA, Wang J, Noblett KL, Larson ER, Sibley DR. Cellular distribution of the rat D4 dopamine receptor protein in the CNS using anti-receptor antisera. Brain Research. 752: 26-34. PMID 9106437 DOI: 10.1016/S0006-8993(96)01422-9 |
0.603 |
|
| 1997 |
Ariano MA, Wang J, Noblett KL, Larson ER, Sibley DR. Cellular distribution of the rat D1B receptor in central nervous system using anti-receptor antisera. Brain Research. 746: 141-50. PMID 9037493 DOI: 10.1016/S0006-8993(96)01219-X |
0.543 |
|
| 1997 |
Friedman E, Jin LQ, Cai GP, Hollon TR, Drago J, Sibley DR, Wang HY. D1-like dopaminergic activation of phosphoinositide hydrolysis is independent of D1A dopamine receptors: evidence from D1A knockout mice. Molecular Pharmacology. 51: 6-11. PMID 9016340 DOI: 10.1124/Mol.51.1.6 |
0.607 |
|
| 1997 |
Waddington JL, Deveney AM, Clifford J, Tighe O, Croke DT, Sibley DR, Drago J. Behavioral Analysis of Multiple DI-Like Dopamine Receptor Subtypes: New Agents and Studies in Transgenic Mice with DIA Receptor Knockout Advances in Pharmacology. 42: 514-517. DOI: 10.1016/S1054-3589(08)60802-9 |
0.432 |
|
| 1997 |
Sibley DR, Ventura ALM, Jiang D, Mak C. Regulation of the DI Dopamine Receptor through cAMP-Mediated Pathways Advances in Pharmacology. 42: 447-450. DOI: 10.1016/S1054-3589(08)60784-X |
0.494 |
|
| 1997 |
Roth BL, Sibley DR. Atypical neuroleptics have low affinity for dopamine D2 receptors or are selective for D4 receptors: Commentary [2] Neuropsychopharmacology. 16: 114-115. DOI: 10.1016/S0893-133X(96)00189-3 |
0.565 |
|
| 1996 |
Liu LX, Monsma FJ, Sibley DR, Chiodo LA. D2L, D2S, and D3 dopamine receptors stably transfected into NG108-15 cells couple to a voltage-dependent potassium current via distinct G protein mechanisms. Synapse (New York, N.Y.). 24: 156-64. PMID 8890457 DOI: 10.1002/(SICI)1098-2396(199610)24:2<156::AID-SYN7>3.0.CO;2-E |
0.589 |
|
| 1996 |
Cravchik A, Sibley DR, Gejman PV. Functional analysis of the human D2 dopamine receptor missense variants. The Journal of Biological Chemistry. 271: 26013-7. PMID 8824240 DOI: 10.1074/Jbc.271.42.26013 |
0.604 |
|
| 1996 |
Levine MS, Altemus KL, Cepeda C, Cromwell HC, Crawford C, Ariano MA, Drago J, Sibley DR, Westphal H. Modulatory actions of dopamine on NMDA receptor-mediated responses are reduced in D1A-deficient mutant mice. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 16: 5870-82. PMID 8795639 DOI: 10.1523/Jneurosci.16-18-05870.1996 |
0.587 |
|
| 1996 |
Chronwall BM, Sands SA, Dickerson DS, Sibley DR, Gary KA. Melanotrope dopamine D2 receptor isoform expression in the developing rat pituitary. International Journal of Developmental Neuroscience : the Official Journal of the International Society For Developmental Neuroscience. 14: 77-86. PMID 8735782 DOI: 10.1016/0736-5748(95)00087-9 |
0.502 |
|
| 1996 |
Accili D, Fishburn CS, Drago J, Steiner H, Lachowicz JE, Park BH, Gauda EB, Lee EJ, Cool MH, Sibley DR, Gerfen CR, Westphal H, Fuchs S. A targeted mutation of the D3 dopamine receptor gene is associated with hyperactivity in mice. Proceedings of the National Academy of Sciences of the United States of America. 93: 1945-9. PMID 8700864 DOI: 10.1073/Pnas.93.5.1945 |
0.581 |
|
| 1996 |
Albrecht FE, Drago J, Felder RA, Printz MP, Eisner GM, Robillard JE, Sibley DR, Westphal HJ, Jose PA. Role of the D1A dopamine receptor in the pathogenesis of genetic hypertension. The Journal of Clinical Investigation. 97: 2283-8. PMID 8636408 DOI: 10.1172/Jci118670 |
0.468 |
|
| 1996 |
Kohen R, Metcalf MA, Khan N, Druck T, Huebner K, Lachowicz JE, Meltzer HY, Sibley DR, Roth BL, Hamblin MW. Cloning, characterization, and chromosomal localization of a human 5-HT6 serotonin receptor. Journal of Neurochemistry. 66: 47-56. PMID 8522988 DOI: 10.1046/J.1471-4159.1996.66010047.X |
0.382 |
|
| 1996 |
Roth B, Hamblin M, Sibley D, Meltzer H. Binding of atypical antipsychotic drugs to novel neurotransmitter receptors Schizophrenia Research. 18: 142. DOI: 10.1016/0920-9964(96)85467-3 |
0.363 |
|
| 1995 |
Roth BL, Tandra S, Burgess LH, Sibley DR, Meltzer HY. D4 dopamine receptor binding affinity does not distinguish between typical and atypical antipsychotic drugs. Psychopharmacology. 120: 365-8. PMID 8524985 DOI: 10.1007/Bf02311185 |
0.536 |
|
| 1995 |
Glatt CE, Snowman AM, Sibley DR, Snyder SH. Clozapine: selective labeling of sites resembling 5HT6 serotonin receptors may reflect psychoactive profile. Molecular Medicine (Cambridge, Mass.). 1: 398-406. PMID 8521297 |
0.41 |
|
| 1995 |
Lachowicz JE, Shen Y, Monsma FJ, Sibley DR. Molecular cloning of a novel G protein-coupled receptor related to the opiate receptor family. Journal of Neurochemistry. 64: 34-40. PMID 7798930 DOI: 10.1046/J.1471-4159.1995.64010034.X |
0.463 |
|
| 1995 |
Ward RP, Hamblin MW, Lachowicz JE, Hoffman BJ, Sibley DR, Dorsa DM. Localization of serotonin subtype 6 receptor messenger RNA in the rat brain by in situ hybridization histochemistry. Neuroscience. 64: 1105-11. PMID 7753378 DOI: 10.1016/0306-4522(94)00439-C |
0.642 |
|
| 1995 |
Gonzalez AM, Sibley DR. [3H]7-OH-DPAT is capable of labeling dopamine D2 as well as D3 receptors. European Journal of Pharmacology. 272: R1-3. PMID 7713138 DOI: 10.1016/0014-2999(94)00738-S |
0.55 |
|
| 1995 |
O'Connell DP, Botkin SJ, Ramos SI, Sibley DR, Ariano MA, Felder RA, Carey RM. Localization of dopamine D1A receptor protein in rat kidneys. The American Journal of Physiology. 268: F1185-97. PMID 7611459 DOI: 10.1152/Ajprenal.1995.268.6.F1185 |
0.504 |
|
| 1995 |
Kreiss DS, Bergstrom DA, Gonzalez AM, Huang KX, Sibley DR, Walters JR. Dopamine receptor agonist potencies for inhibition of cell firing correlate with dopamine D3 receptor binding affinities. European Journal of Pharmacology. 277: 209-14. PMID 7493610 DOI: 10.1016/0014-2999(95)00069-W |
0.638 |
|
| 1995 |
Chase TN, Metman LV, Bravi D, Roberts JW, Sibley DR, Mouradian MM. Dopamine-receptor subtype-selective agonists in the treatment of Parkinson's disease Clinical Neuropharmacology. 18: S207-S215. DOI: 10.1097/00002826-199501001-00022 |
0.532 |
|
| 1995 |
Ariano MA, Sibley DR. [21] Development of antireceptor antibodies using synthetic peptides Methods in Neurosciences. 25: 455-469. DOI: 10.1016/S1043-9471(05)80051-5 |
0.595 |
|
| 1995 |
Glatt CE, Snowman AM, Sibley DR, Snyder SH. Clozapine: Selective Labeling of Sites Resembling 5HT6 Serotonin Receptors May Reflect Psychoactive Profile Molecular Medicine. 1: 398-406. DOI: 10.1007/BF03401577 |
0.536 |
|
| 1994 |
Chronwall BM, Dickerson DS, Huerter BS, Sibley DR, Millington WR. Regulation of heterogeneity in D2 dopamine receptor gene expression among individual melanotropes in the rat pituitary intermediate lobe. Molecular and Cellular Neurosciences. 5: 35-45. PMID 8087413 DOI: 10.1006/Mcne.1994.1004 |
0.569 |
|
| 1994 |
Ariano MA, Sibley DR. Dopamine receptor distribution in the rat CNS: elucidation using anti-peptide antisera directed against D1A and D3 subtypes. Brain Research. 649: 95-110. PMID 7953659 DOI: 10.1016/0006-8993(94)91052-9 |
0.606 |
|
| 1994 |
Zhang LJ, Lachowicz JE, Sibley DR. The D2S and D2L dopamine receptor isoforms are differentially regulated in Chinese hamster ovary cells. Molecular Pharmacology. 45: 878-89. PMID 7910658 |
0.555 |
|
| 1994 |
Black LE, Smyk-Randall EM, Sibley DR. Cyclic AMP-mediated desensitization of D1 dopamine receptor-coupled adenylyl cyclase in NS20Y neuroblastoma cells. Molecular and Cellular Neurosciences. 5: 567-75. PMID 7704430 DOI: 10.1006/mcne.1994.1069 |
0.584 |
|
| 1994 |
Fisher RS, Levine MS, Sibley DR, Ariano MA. D2 dopamine receptor protein location: Golgi impregnation-gold toned and ultrastructural analysis of the rat neostriatum. Journal of Neuroscience Research. 38: 551-64. PMID 7529326 DOI: 10.1002/jnr.490380508 |
0.543 |
|
| 1994 |
Monsma FJ, Burgess LH, Sibley DR, Civelli O. Dopamine D1 and D5 receptors: molecular cloning and pharmacological characteristics European Neuropsychopharmacology. 4: 194-195. DOI: 10.1016/0924-977X(94)90032-9 |
0.583 |
|
| 1994 |
Sibley DR. The G-protein linked receptor facts book Trends in Pharmacological Sciences. 15: 431-432. DOI: 10.1016/0165-6147(94)90094-9 |
0.45 |
|
| 1993 |
Chronwall BM, Dickerson DS, Sibley DR, Gary KA. Plasticity and ontogeny of melanotrope D2A dopamine receptor mRNA and isoform protein expression. Annals of the New York Academy of Sciences. 680: 478-80. PMID 8512223 DOI: 10.1111/J.1749-6632.1993.Tb19713.X |
0.503 |
|
| 1993 |
Wagner HJ, Luo BG, Ariano MA, Sibley DR, Stell WK. Localization of D2 dopamine receptors in vertebrate retinae with anti-peptide antibodies. The Journal of Comparative Neurology. 331: 469-81. PMID 8509505 DOI: 10.1002/Cne.903310404 |
0.537 |
|
| 1993 |
Ariano MA, Fisher RS, Smyk-Randall E, Sibley DR, Levine MS. D2 dopamine receptor distribution in the rodent CNS using anti-peptide antisera. Brain Research. 609: 71-80. PMID 8508323 DOI: 10.1016/0006-8993(93)90857-J |
0.611 |
|
| 1993 |
Felder RA, Kinoshita S, Ohbu K, Mouradian MM, Sibley DR, Monsma FJ, Minowa T, Minowa MT, Canessa LM, Jose PA. Organ specificity of the dopamine1 receptor/adenylyl cyclase coupling defect in spontaneously hypertensive rats. The American Journal of Physiology. 264: R726-32. PMID 8476116 DOI: 10.1152/Ajpregu.1993.264.4.R726 |
0.374 |
|
| 1993 |
Sibley DR, Monsma FJ, Shen Y. Molecular neurobiology of dopaminergic receptors. International Review of Neurobiology. 35: 391-415. PMID 8463063 DOI: 10.1016/S0074-7742(08)60573-5 |
0.621 |
|
| 1993 |
Yamaguchi I, Jose PA, Mouradian MM, Canessa LM, Monsma FJ, Sibley DR, Takeyasu K, Felder RA. Expression of dopamine D1A receptor gene in proximal tubule of rat kidneys. The American Journal of Physiology. 264: F280-5. PMID 8447437 DOI: 10.1152/Ajprenal.1993.264.2.F280 |
0.43 |
|
| 1993 |
Shen Y, Monsma FJ, Metcalf MA, Jose PA, Hamblin MW, Sibley DR. Molecular cloning and expression of a 5-hydroxytryptamine7 serotonin receptor subtype. The Journal of Biological Chemistry. 268: 18200-4. PMID 8394362 |
0.344 |
|
| 1993 |
Castellano MA, Liu LX, Monsma FJ, Sibley DR, Kapatos G, Chiodo LA. Transfected D2 short dopamine receptors inhibit voltage-dependent potassium current in neuroblastoma x glioma hybrid (NG108-15) cells. Molecular Pharmacology. 44: 649-56. PMID 8371717 |
0.395 |
|
| 1993 |
David C, Fishburn CS, Monsma FJ, Sibley DR, Fuchs S. Synthesis and processing of D2 dopamine receptors. Biochemistry. 32: 8179-83. PMID 8347618 |
0.519 |
|
| 1993 |
Monsma FJ, Shen Y, Ward RP, Hamblin MW, Sibley DR. Cloning and expression of a novel serotonin receptor with high affinity for tricyclic psychotropic drugs. Molecular Pharmacology. 43: 320-7. PMID 7680751 |
0.418 |
|
| 1992 |
Xu SX, Monsma FJ, Sibley DR, Creese I. Regulation of D1A and D2 dopamine receptor mRNA during ontogenesis, lesion and chronic antagonist treatment. Life Sciences. 50: 383-96. PMID 1732708 DOI: 10.1016/0024-3205(92)90440-Z |
0.694 |
|
| 1992 |
Sibley DR, Monsma FJ. Molecular biology of dopamine receptors. Trends in Pharmacological Sciences. 13: 61-9. PMID 1561715 DOI: 10.1016/0165-6147(92)90025-2 |
0.578 |
|
| 1992 |
Minowa MT, Minowa T, Monsma FJ, Sibley DR, Mouradian MM. Characterization of the 5' flanking region of the human D1A dopamine receptor gene. Proceedings of the National Academy of Sciences of the United States of America. 89: 3045-9. PMID 1557411 DOI: 10.1073/Pnas.89.7.3045 |
0.355 |
|
| 1992 |
Ariano MA, Stromski CJ, Smyk-Randall EM, Sibley DR. D2 dopamine receptor localization on striatonigral neurons. Neuroscience Letters. 144: 215-20. PMID 1436705 DOI: 10.1016/0304-3940(92)90753-T |
0.628 |
|
| 1992 |
Creese I, Sibley DR, Xu SX. Expression of rat striatal D1 and D2 dopamine receptor mRNAs: ontogenetic and pharmacological studies. Neurochemistry International. 20: 45S-48S. PMID 1365454 DOI: 10.1016/0197-0186(92)90209-A |
0.682 |
|
| 1992 |
Sibley DR, Monsma FJ, McVittie LD, Gerfen CR, Burch RM, Mahan LC. Molecular neurobiology of dopamine receptor subtypes. Neurochemistry International. 20: 17S-22S. PMID 1365419 DOI: 10.1016/0197-0186(92)90205-6 |
0.578 |
|
| 1991 |
Sibley DR. Cloning of a 'D3' receptor subtype expands dopamine receptor family. Trends in Pharmacological Sciences. 12: 7-9. PMID 2006541 DOI: 10.1016/0165-6147(91)90480-G |
0.608 |
|
| 1991 |
Ariano MA, Kang HC, Haugland RP, Sibley DR. Multiple fluorescent ligands for dopamine receptors. II. Visualization in neural tissues. Brain Research. 547: 208-22. PMID 1884196 DOI: 10.1016/0006-8993(91)90964-W |
0.609 |
|
| 1991 |
Mahan LC, McVittie LD, Smyk-Randall EM, Nakata H, Monsma FJ, Gerfen CR, Sibley DR. Cloning and expression of an A1 adenosine receptor from rat brain. Molecular Pharmacology. 40: 1-7. PMID 1857334 |
0.385 |
|
| 1991 |
Kanterman RY, Mahan LC, Briley EM, Monsma FJ, Sibley DR, Axelrod J, Felder CC. Transfected D2 dopamine receptors mediate the potentiation of arachidonic acid release in Chinese hamster ovary cells. Molecular Pharmacology. 39: 364-9. PMID 1848657 |
0.452 |
|
| 1991 |
McVittie LD, Ariano MA, Sibley DR. Characterization of anti-peptide antibodies for the localization of D2 dopamine receptors in rat striatum. Proceedings of the National Academy of Sciences of the United States of America. 88: 1441-5. PMID 1825357 DOI: 10.1073/Pnas.88.4.1441 |
0.442 |
|
| 1991 |
Barton AC, Kang HC, Rinaudo MS, Monsma FJ, Stewart-Fram RM, Macinko JA, Haugland RP, Ariano MA, Sibley DR. Multiple fluorescent ligands for dopamine receptors. I. Pharmacological characterization and receptor selectivity. Brain Research. 547: 199-207. PMID 1679366 DOI: 10.1016/0006-8993(91)90963-V |
0.562 |
|
| 1991 |
Barton AC, Black LE, Sibley DR. Agonist-induced desensitization of D2 dopamine receptors in human Y-79 retinoblastoma cells. Molecular Pharmacology. 39: 650-8. PMID 1674585 |
0.522 |
|
| 1991 |
Xu SX, Hatada Y, Black LE, Creese I, Sibley DR. N-(p-isothiocyanatophenethyl)spiperone, a selective and irreversible antagonist of D2 dopamine receptors in brain. The Journal of Pharmacology and Experimental Therapeutics. 257: 608-15. PMID 1674530 |
0.735 |
|
| 1990 |
Monsma FJ, Mahan LC, McVittie LD, Gerfen CR, Sibley DR. Molecular cloning and expression of a D1 dopamine receptor linked to adenylyl cyclase activation. Proceedings of the National Academy of Sciences of the United States of America. 87: 6723-7. PMID 2168556 DOI: 10.1073/Pnas.87.17.6723 |
0.563 |
|
| 1990 |
Gerfen CR, Engber TM, Mahan LC, Susel Z, Chase TN, Monsma FJ, Sibley DR. D1 and D2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons. Science (New York, N.Y.). 250: 1429-32. PMID 2147780 DOI: 10.1126/Science.2147780 |
0.537 |
|
| 1990 |
Barton AC, Sibley DR. Agonist-induced desensitization of D1-dopamine receptors linked to adenylyl cyclase activity in cultured NS20Y neuroblastoma cells. Molecular Pharmacology. 38: 531-41. PMID 1978240 |
0.563 |
|
| 1990 |
Monsma FJ, Barton AC, Sibley DR. Expression of functional D2 dopamine receptors following differentiation of Y-79 human retinoblastoma cells. Journal of Neurochemistry. 54: 1200-7. PMID 1968958 DOI: 10.1111/J.1471-4159.1990.Tb01949.X |
0.542 |
|
| 1990 |
Mahan LC, Burch RM, Monsma FJ, Sibley DR. Expression of striatal D1 dopamine receptors coupled to inositol phosphate production and Ca2+ mobilization in Xenopus oocytes. Proceedings of the National Academy of Sciences of the United States of America. 87: 2196-200. PMID 1690425 DOI: 10.1073/Pnas.87.6.2196 |
0.515 |
|
| 1989 |
Monsma FJ, Brassard DL, Sibley DR. Identification and characterization of D1 and D2 dopamine receptors in cultured neuroblastoma and retinoblastoma clonal cell lines. Brain Research. 492: 314-24. PMID 2665904 DOI: 10.1016/0006-8993(89)90915-3 |
0.593 |
|
| 1989 |
McVittie LD, Sibley DR. Solubilization of phencyclidine receptors from rat cerebral cortex in an active ligand binding state. Life Sciences. 44: 1793-802. PMID 2543880 DOI: 10.1016/0024-3205(89)90567-5 |
0.418 |
|
| 1989 |
Monsma FJ, Sibley DR. Direct demonstration of D1 dopamine receptors in the bovine parathyroid gland using the D1 selective antagonist [125I]-SCH 23982. Synapse (New York, N.Y.). 3: 193-9. PMID 2524116 DOI: 10.1002/syn.890030304 |
0.591 |
|
| 1989 |
Monsma FJ, Barton AC, Kang HC, Brassard DL, Haugland RP, Sibley DR. Characterization of novel fluorescent ligands with high affinity for D1 and D2 dopaminergic receptors. Journal of Neurochemistry. 52: 1641-4. PMID 2523470 DOI: 10.1111/J.1471-4159.1989.Tb09220.X |
0.575 |
|
| 1989 |
Munemura M, Agui T, Sibley DR. Chronic estrogen treatment promotes a functional uncoupling of the D2 dopamine receptor in rat anterior pituitary gland. Endocrinology. 124: 346-55. PMID 2521206 DOI: 10.1210/endo-124-1-346 |
0.536 |
|
| 1989 |
Monsma FJ, McVittie LD, Gerfen CR, Mahan LC, Sibley DR. Multiple D2 dopamine receptors produced by alternative RNA splicing. Nature. 342: 926-9. PMID 2480527 DOI: 10.1038/342926a0 |
0.62 |
|
| 1989 |
Ariano MA, Monsma FJ, Barton AC, Kang HC, Haugland RP, Sibley DR. Direct visualization and cellular localization of D1 and D2 dopamine receptors in rat forebrain by use of fluorescent ligands. Proceedings of the National Academy of Sciences of the United States of America. 86: 8570-4. PMID 2479025 DOI: 10.1073/Pnas.86.21.8570 |
0.584 |
|
| 1988 |
Yang SD, Fong YL, Benovic JL, Sibley DR, Caron MG, Lefkowitz RJ. Dephosphorylation of the beta 2-adrenergic receptor and rhodopsin by latent phosphatase 2. The Journal of Biological Chemistry. 263: 8856-8. PMID 2837466 |
0.543 |
|
| 1988 |
Sibley DR, Benovic JL, Caron MG, Lefkowitz RJ. Phosphorylation of cell surface receptors: a mechanism for regulating signal transduction pathways. Endocrine Reviews. 9: 38-56. PMID 2836188 DOI: 10.1210/Edrv-9-1-38 |
0.76 |
|
| 1988 |
Sibley DR. Dopamine Receptors.Ian Creese , Claire M. Fraser The Quarterly Review of Biology. 63: 359-359. DOI: 10.1086/416005 |
0.434 |
|
| 1988 |
Sibley DR, Lefkowitz RJ. Biochemical mechanisms of β-adrenergic receptor regulation Isi Atlas of Science: Pharmacology. 2: 66-70. |
0.35 |
|
| 1987 |
Yoshimasa T, Sibley DR, Bouvier M, Lefkowitz RJ, Caron MG. Cross-talk between cellular signalling pathways suggested by phorbol-ester-induced adenylate cyclase phosphorylation. Nature. 327: 67-70. PMID 3033513 DOI: 10.1038/327067A0 |
0.773 |
|
| 1987 |
Sibley DR, Benovic JL, Caron MG, Lefkowitz RJ. Regulation of transmembrane signaling by receptor phosphorylation. Cell. 48: 913-22. PMID 3030559 DOI: 10.1016/0092-8674(87)90700-8 |
0.782 |
|
| 1987 |
Sibley DR, Lefkowitz RJ. Beta-adrenergic receptor-coupled adenylate cyclase. Biochemical mechanisms of regulation. Molecular Neurobiology. 1: 121-54. PMID 2855789 DOI: 10.1007/BF02935266 |
0.618 |
|
| 1987 |
Sibley DR, Benovic JL, Caron MG, Lefkowitz RJ. Molecular mechanisms of beta-adrenergic receptor desensitization. Advances in Experimental Medicine and Biology. 221: 253-73. PMID 2829583 DOI: 10.1007/978-1-4684-7618-7_19 |
0.757 |
|
| 1987 |
Sibley DR, Daniel K, Strader CD, Lefkowitz RJ. Phosphorylation of the beta-adrenergic receptor in intact cells: relationship to heterologous and homologous mechanisms of adenylate cyclase desensitization. Archives of Biochemistry and Biophysics. 258: 24-32. PMID 2444163 DOI: 10.1016/0003-9861(87)90318-3 |
0.582 |
|
| 1986 |
Sibley DR, Jeffs RA, Daniel K, Nambi P, Lefkowitz RJ. Phorbol diester treatment promotes enhanced adenylate cyclase activity in frog erythrocytes. Archives of Biochemistry and Biophysics. 244: 373-81. PMID 3484932 DOI: 10.1016/0003-9861(86)90126-8 |
0.678 |
|
| 1986 |
Sibley DR, Lefkowitz RJ. Adenylate cyclase coupled beta-adrenergic receptors: biochemical mechanisms of desensitization. Clinical Neuropharmacology. 9: 3-5. PMID 3032428 |
0.481 |
|
| 1986 |
Sibley DR, Strasser RH, Benovic JL, Daniel K, Lefkowitz RJ. Phosphorylation/dephosphorylation of the beta-adrenergic receptor regulates its functional coupling to adenylate cyclase and subcellular distribution. Proceedings of the National Academy of Sciences of the United States of America. 83: 9408-12. PMID 3025843 DOI: 10.1073/Pnas.83.24.9408 |
0.763 |
|
| 1986 |
Strasser RH, Sibley DR, Lefkowitz RJ. A novel catecholamine-activated adenosine cyclic 3',5'-phosphate independent pathway for beta-adrenergic receptor phosphorylation in wild-type and mutant S49 lymphoma cells: mechanism of homologous desensitization of adenylate cyclase. Biochemistry. 25: 1371-7. PMID 3008828 DOI: 10.1021/Bi00354A027 |
0.678 |
|
| 1986 |
Nambi P, Peters JR, Sibley DR, Lefkowitz RJ. Cell-free desensitization of the β-adrenergic receptor: Evidence that multiple protein kinases can phosphorylate and desensitize the receptor Annals of the New York Academy of Sciences. 122-124. DOI: 10.1111/J.1749-6632.1986.Tb21519.X |
0.741 |
|
| 1986 |
NAMBI P, PETERS JR, SIBLEY DR, LEFKOWITZ RJ. Cell-free Desensitization of the ?-Adrenergic Receptor: Evidence that Multiple Protein Kinases Can Phosphorylate and Desensitize the Receptor Annals of the New York Academy of Sciences. 463: 122-124. DOI: 10.1111/j.1749-6632.1986.tb21519.x |
0.718 |
|
| 1985 |
Nambi P, Sibley DR, Lefkowitz RJ. Sensitization of frog erythrocyte adenylate cyclase system by tumor-promoting phorbol diesters. Canadian Journal of Physiology and Pharmacology. 63: 983-6. PMID 3878225 DOI: 10.1139/Y85-162 |
0.644 |
|
| 1985 |
Sibley DR, Lefkowitz RJ. Molecular mechanisms of receptor desensitization using the beta-adrenergic receptor-coupled adenylate cyclase system as a model. Nature. 317: 124-9. PMID 2993919 DOI: 10.1038/317124a0 |
0.618 |
|
| 1985 |
Nambi P, Peters JR, Sibley DR, Lefkowitz RJ. Desensitization of the turkey erythrocyte beta-adrenergic receptor in a cell-free system. Evidence that multiple protein kinases can phosphorylate and desensitize the receptor. The Journal of Biological Chemistry. 260: 2165-71. PMID 2982811 |
0.491 |
|
| 1985 |
Sibley DR, Strasser RH, Caron MG, Lefkowitz RJ. Homologous desensitization of adenylate cyclase is associated with phosphorylation of the beta-adrenergic receptor. The Journal of Biological Chemistry. 260: 3883-6. PMID 2858484 |
0.548 |
|
| 1985 |
Sibley DR, Strasser RH, Caron MG, Lefkowitz RJ. Homologous desensitization of adenylate cyclase is associated with phosphorylation of the β-adrenergic receptor Federation Proceedings. 44: No. 7117. |
0.361 |
|
| 1985 |
Nambi P, Peters JR, Sibley DR, Lefkowitz RJ. Desensitization and phosphorylation of turkey erythrocyte β-adrenergic receptors in a cell-free system Federation Proceedings. 44: No. 8093. |
0.349 |
|
| 1984 |
McDonald WM, Sibley DR, Kilpatrick BF, Caron MG. Dopaminergic inhibition of adenylate cyclase correlates with high affinity agonist binding to anterior pituitary D2 dopamine receptors. Molecular and Cellular Endocrinology. 36: 201-9. PMID 6540722 DOI: 10.1016/0303-7207(84)90037-6 |
0.666 |
|
| 1984 |
Creese I, Sibley DR, Leff SE. Agonist interactions with dopamine receptors: focus on radioligand-binding studies. Federation Proceedings. 43: 2779-84. PMID 6383871 |
0.712 |
|
| 1984 |
Sibley DR, Nambi P, Peters JR, Lefkowitz RJ. Phorbol diesters promote beta-adrenergic receptor phosphorylation and adenylate cyclase desensitization in duck erythrocytes. Biochemical and Biophysical Research Communications. 121: 973-9. PMID 6331437 |
0.696 |
|
| 1984 |
Sibley DR, Peters JR, Nambi P, Caron MG, Lefkowitz RJ. Photoaffinity labeling of turkey erythrocyte beta-adrenergic receptors: degradation of the Mr = 49,000 protein explains apparent heterogeneity. Biochemical and Biophysical Research Communications. 119: 458-64. PMID 6324763 DOI: 10.1016/S0006-291X(84)80271-5 |
0.715 |
|
| 1984 |
Nambi P, Sibley DR, Stadel JM, Michel T, Peters JR, Lefkowitz RJ. Cell-free desensitization of catecholamine-sensitive adenylate cyclase. Agonist- and cAMP-promoted alterations in turkey erythrocyte beta-adrenergic receptors. The Journal of Biological Chemistry. 259: 4629-33. PMID 6323481 |
0.516 |
|
| 1984 |
Peters JR, Nambi P, Sibley DR, Lefkowitz RJ. Enhanced adenylate cyclase activity of turkey erythrocytes following treatment with beta-adrenergic receptor antagonists. European Journal of Pharmacology. 107: 43-52. PMID 6151904 DOI: 10.1016/0014-2999(84)90089-X |
0.738 |
|
| 1984 |
Nambi P, Sibley DR, Caron MG, Lefkowitz RJ. Photoaffinity labeling of beta-adrenergic receptors in mammalian tissues. Biochemical Pharmacology. 33: 3813-22. PMID 6095862 DOI: 10.1016/0006-2952(84)90045-5 |
0.684 |
|
| 1984 |
Strader CD, Sibley DR, Lefkowitz RJ. Association of sequestered beta-adrenergic receptors with the plasma membrane: a novel mechanism for receptor down regulation. Life Sciences. 35: 1601-10. PMID 6090842 DOI: 10.1016/0024-3205(84)90359-X |
0.54 |
|
| 1984 |
Cerione RA, Sibley DR, Codina J, Benovic JL, Winslow J, Neer EJ, Birnbaumer L, Caron MG, Lefkowitz RJ. Reconstitution of a hormone-sensitive adenylate cyclase system. The pure beta-adrenergic receptor and guanine nucleotide regulatory protein confer hormone responsiveness on the resolved catalytic unit. The Journal of Biological Chemistry. 259: 9979-82. PMID 6088509 |
0.425 |
|
| 1984 |
Sibley DR, Peters JR, Nambi P, Caron MG, Lefkowitz RJ. Desensitization of turkey erythrocyte adenylate cyclase. Beta-adrenergic receptor phosphorylation is correlated with attenuation of adenylate cyclase activity. The Journal of Biological Chemistry. 259: 9742-9. PMID 6086645 |
0.541 |
|
| 1983 |
Sibley DR, Mahan LC, Creese I. Dopamine receptor binding on intact cells. Absence of a high-affinity agonist-receptor binding state. Molecular Pharmacology. 23: 295-302. PMID 6835198 |
0.698 |
|
| 1983 |
Sibley DR, Creese I. Regulation of ligand binding to pituitary D-2 dopaminergic receptors. Effects of divalent cations and functional group modification. The Journal of Biological Chemistry. 258: 4957-65. PMID 6833284 |
0.63 |
|
| 1983 |
Caron MG, Kilpatrick BF, Sibley DR. Direct radioligand measurement of dopamine receptors in the anterior pituitary gland. Methods in Enzymology. 103: 557-90. PMID 6669043 DOI: 10.1016/S0076-6879(83)03041-4 |
0.726 |
|
| 1983 |
Creese I, Sibley DR, Leff S. Classification of dopamine receptors. Advances in Biochemical Psychopharmacology. 37: 255-66. PMID 6416028 |
0.715 |
|
| 1983 |
Creese I, Sibley DR, Hamblin MW, Leff SE. Dopamine receptors in the central nervous system. Advances in Biochemical Psychopharmacology. 36: 125-34. PMID 6344562 DOI: 10.1016/B978-008055232-3.60151-5 |
0.718 |
|
| 1983 |
Sibley DR, Creese I. Interactions of ergot alkaloids with anterior pituitary D-2 dopamine receptors. Molecular Pharmacology. 23: 585-93. PMID 6223205 |
0.7 |
|
| 1983 |
Creese I, Sibley DR, Hamblin MW, Leff SE. The classification of dopamine receptors: relationship to radioligand binding. Annual Review of Neuroscience. 6: 43-71. PMID 6220666 DOI: 10.1146/Annurev.Ne.06.030183.000355 |
0.72 |
|
| 1983 |
Creese I, Morrow AL, Hamblin MW, Leff SE, Sibley DR. Radioligand binding studies of dopamine receptors in the central nervous system Advances in the Biosciences. 44: 1-50. |
0.713 |
|
| 1982 |
Dahms AS, Sibley D, Huisman W, Donald A. D-Galactonate dehydratase. Methods in Enzymology. 90: 294-8. PMID 7154959 DOI: 10.1016/S0076-6879(82)90143-4 |
0.671 |
|
| 1982 |
Sibley DR, Weinberger S, Segal DS, Creese I. Multiple daily amphetamine administration decreases both [3H]agonist and [3H]antagonist dopamine receptor binding. Experientia. 38: 1224-5. PMID 6890464 DOI: 10.1007/BF01959753 |
0.67 |
|
| 1982 |
Creese I, Morrow AL, Leff SE, Sibley DR, Hamblin MW. Dopamine receptors in the central nervous system. International Review of Neurobiology. 23: 255-301. PMID 6749737 |
0.778 |
|
| 1982 |
Sibley DR, De Lean A, Creese I. Anterior pituitary dopamine receptors. Demonstration of interconvertible high and low affinity states of the D-2 dopamine receptor. The Journal of Biological Chemistry. 257: 6351-61. PMID 6176582 |
0.665 |
|
| 1982 |
Sibley DR, Leff SE, Creese I. Interactions of novel dopaminergic ligands with D-1 and D-2 dopamine receptors. Life Sciences. 31: 637-45. PMID 6127585 DOI: 10.1016/0024-3205(82)90764-0 |
0.743 |
|
| 1982 |
Creese I, Sibley DR. Comments on the commentary by Dr. Seeman Biochemical Pharmacology. 31: 2568-2569. DOI: 10.1016/0006-2952(82)90701-8 |
0.518 |
|
| 1981 |
Leff S, Sibley DR, Hamblin M, Creese I. Ascorbic acid enables reversible dopamine receptor 3H-agonist binding. Life Sciences. 29: 2081-90. PMID 7311734 DOI: 10.1016/0024-3205(81)90665-2 |
0.687 |
|
| 1981 |
Creese I, Sibley DR, Leff S, Hamblin M. Dopamine receptors: subtypes, localization and regulation. Federation Proceedings. 40: 147-52. PMID 7007083 |
0.735 |
|
| 1981 |
Creese I, Sibley DR. Receptor adaptations to centrally acting drugs. Annual Review of Pharmacology and Toxicology. 21: 357-91. PMID 6263174 DOI: 10.1146/annurev.pa.21.040181.002041 |
0.663 |
|
| 1980 |
Sibley DR, Creese I. Dopamine receptor binding in bovine intermediate lobe pituitary membranes. Endocrinology. 107: 1405-9. PMID 7428676 DOI: 10.1210/endo-107-5-1405 |
0.593 |
|
| 1980 |
Sibley DR, Creese I. Pseudo non-competitive agonist interactions with dopamine receptors. European Journal of Pharmacology. 65: 131-3. PMID 7398773 |
0.715 |
|
| 1979 |
Creese I, Sibley DR. Radioligand binding studies: evidence for multiple dopamine receptors. Communications in Psychopharmacology. 3: 385-95. PMID 546587 |
0.713 |
|
| 1979 |
Sibley DR, Creese I. Guanine nucleotides regulate anterior pituitary dopamine receptors. European Journal of Pharmacology. 55: 341-3. PMID 456433 DOI: 10.1016/0014-2999(79)90207-3 |
0.712 |
|
| Show low-probability matches. |